Login to Your Account

ImClone Nixes BMS Proposal, Says a New Suitor has Called

By Catherine Hollingsworth

Thursday, September 11, 2008
Carl Icahn, chairman of the board at ImClone Systems Inc., said the board's special committee has rejected a buyout offer from Bristol-Myers Squibb Co., and will consider a higher bid from an unnamed large pharmaceutical company. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription